1. Prosonix Announce Agreement With Trimel Biopharma
(News/Latest)

Prosonix has announced that it has entered into a multi-product co-development and licensing agreement with Trimel Biopharma (a subsidiary of Trimel Biopharma Holdings -Barbados) in order to collaborate ...

2. Prosonix Announce Agreement With Trimel Biopharma
(News/Newsflash)

Prosonix has announced that it has entered into a multi-product co-development and licensing agreement with Trimel Biopharma (a subsidiary of Trimel Biopharma Holdings -Barbados) in order to collaborate ...

3. Welcome to the Blog
(Blog/blog)

This is Prosonix new blog page, welcome! Please feel free to add your comments  ...

4. Scale-up of co-crystals
(Blog/blog)

... to batch processes, it seemed there could be some mileage in applying this approach to co-crystals. I think ultrasound might help. I would be interested to hear if other people or Prosonix have explored ...

5. Contacts List
(About us/about us)

The following people are on the Prosonix contact list. Their position within the organisation is shown alongside the name. If you wish to contact any of us please click on the contact name and you will ...

6. September 1-3, 2010: The Science of Medicines, Nottingham, UK
(events/events)

Prosonix CEO David Hipkiss will be presenting at the Academy of Pharmaceutical Sciences inaugural science conference UK-PharmSci 2010 entitled The Science of Medicines taking place 1-3 September 2010 at ...

7. Prosonix Announce The Scale-Up Of UMAX technology
(News/Latest)

In just a short space of time since its launch Prosonix has successfully scaled up of the UMAX® particle engineering technology. The scale-up has now been carried out on several APIs in cGMP facilities ...

8. Prosonix Announce The Scale-Up Of UMAX technology
(News/Newsflash)

In just a short space of time since its launch Prosonix has successfully scaled up of the UMAX® particle engineering technology. The scale-up has now been carried out on several APIs in cGMP facilities ...

9. November 3-4, 2010: Crystallization & Polymorphism, Florida
(events/events)

Prosonix CTO Dr Graham Ruecroft will be presenting and chairing a seesion at the 9th International Conference and Exhibition on Polymorphism & Crystallization organised by Scientific Update, UK, taking ...

10. Prosonix CEO David Hipkiss talks to in-Pharma
(News/Latest)

David Hipkiss, CEO of Prosonix, recently spoke to in-Pharma technologist.com about the company's recent launch of its new UMAX® particle engineering technology and how it is set to revolutionise the field ...

11. Prosonix CEO, David Hipkiss talks to in-Pharma
(News/Newsflash)

David Hipkiss, CEO of Prosonix, recently spoke to in-Pharma technologist.com about the company's recent launch of its new UMAX® particle engineering technology and how it is set to revolutionise the field ...

12. Prosonix Announce The Launch Of UMAX technology
(News/Latest)

Prosonix is pleased to announce the launch of its UMAX® technology - an acronym for Ultrasound Mediated Amorphous to Crystalline transition - which is a new disruptive particle engineering technology set ...

13. Prosonix Announce The Launch Of UMAX technology
(News/Newsflash)

Prosonix is pleased to announce the launch of its UMAX® technology - an acronym for Ultrasound Mediated Amorphous to Crystalline transition - which is a new disruptive particle engineering technology set ...

14. UMAX Pharmaceutical Particle Engineering
(technology/Technology)

The Prosonix power ultrasound assisted particle engineering technology UMAX®, (Ultrasound Mediated Amorphous to Crystalline transition) can be used for the manufacture of optimal particles designed and ...

15. In-house Development Pipeline
(Pharmaceuticals/Pharmaceuticals)

Prosonix welcomes enquiries from all parties interested in licensing and co-development opportunities. Please contact David Hipkiss CEO or Christian Jones BDM or Contact us In-house development pipeline ...

16. Partnered Development Pipeline
(Pharmaceuticals/Pharmaceuticals)

Prosonix welcomes enquiries from all parties interested in licensing and co-development opportunities. Please contact David Hipkiss CEO or Christian Jones BDM or Contact us Partnered development pipeline ...

17. Product Pipeline - Making Better Medicines
(Pharmaceuticals/Pharmaceuticals)

Prosonix is developing a portfolio of engineered pharmaceutical mono and combination inhalation therapy products that offer distinct and high value advantages to patients.  With proven delivery across ...

18. Prosonix CEO David Hipkiss talks to CHEManager
(News/Latest)

David Hipkiss, CEO of Prosonix, recently spoke to CHEM-anager Europe about the company's endeavours in using its proprietary sonocrystallization and particle engineering technologies for Making Better ...

19. Prosonix Wins Award at Major Conference- DDL-20
(News/Latest)

Prosonix was delighted to win the best industrial poster award at Europe's premier conference and exhibition dedicated to pulmonary and nasal drug delivery, namely Drug Delivery to the Lungs - DDL20, ...

20. Prosonix Wins Poster Award at DDL-20
(News/Newsflash)

Prosonix was delighted to win the best industrial poster award at Europe's premier conference and exhibition dedicated to pulmonary and nasal drug delivery, namely Drug Delivery to the Lungs - DDL20, ...